Blockbuster buzz: 15 top therapies in late-stage development Submitted by admin on Thu, 10/11/2012 - 10:39 Read more about Blockbuster buzz: 15 top therapies in late-stage development Source Fierce Biotech Headline Blockbuster buzz: 15 top therapies in late-stage development News Tags vortioxetine Vectura tofacitinib Takeda T-DM1 Sanofi Roche REGN727 Regeneron Reata QVA149 Pfizer Odanacatib Novartis MorphoSys Merck macitentan Lundbeck Immunogen GSK GS-7977 Gilead gantenerumab Eliquis darapladib Bristol-Myers Squibb Biogen Idec BG-12 Bayer Bardoxolone Anacetrapib Alpharadin Algeta Actelion AbbVie
Bayer predicts blockbuster success for four of its late-stage drugs Submitted by admin on Tue, 12/20/2011 - 11:24 Read more about Bayer predicts blockbuster success for four of its late-stage drugs Source Fierce Biotech Headline Bayer predicts blockbuster success for four of its late-stage drugs News Tags Bayer Xarelto VEGF Trap-Eye regorafenib Alpharadin
Bayer Drug Hailed As Prostate Cancer Game Changer Submitted by admin on Mon, 09/26/2011 - 11:39 Read more about Bayer Drug Hailed As Prostate Cancer Game Changer Source TheStreet.com Headline Bayer Drug Hailed As Prostate Cancer Game Changer News Tags Bayer prostate cancer Algeta Amgen Xgeva Exelixis Alpharadin
First Phase III trial of an alpha-pharmaceutical Submitted by admin on Sat, 09/24/2011 - 13:26 Read more about First Phase III trial of an alpha-pharmaceutical Source eurekalert.org Headline First Phase III trial of an alpha-pharmaceutical News Tags Bone metastases prostate cancer Alpharadin Algeta Bayer
Bayer to Pay Up to $800 Million for Algeta’s New Drug Submitted by admin on Thu, 09/03/2009 - 08:45 Read more about Bayer to Pay Up to $800 Million for Algeta’s New Drug Source Bloomberg Headline Bayer to Pay Up to $800 Million for Algeta’s New Drug News Tags Bayer Algeta Alpharadin prostate cancer